Royalty Report: Drugs, Therapeutic, Biotechnology – Collection: 27617


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Biotechnology
  • Diagnostic
  • Pharmaceuticals
  • cell therapy
  • Supply

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27617

License Grant
The parties are collaborating on a variety of indications utilizing PLX cells. According to the agreement, the Licensee be the exclusive owner of the technology and any products produced as a result of the collaboration.
License Property
The patented PLX (PLacental eXpanded) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals, generated by the patient’s own body. PLX cells are grown using proprietary 3D micro-environment technology that produces a product requiring no tissue matching prior to administration.
Field of Use
PLX cells may be effective in supporting bone marrow transplantation and in treating bone marrow suppression from radiation and chemotherapy.

IPSCIO Record ID: 26630

License Grant
The Licensor granted Exclusive Marketing rights to the Licensee, for the PLX I technology for therapeutic applications.

Also included in the License are the rights to use the PLX I technology in Stem Cell's in-vitro screening applications, if any, worldwide.

License Property
The PLX I technology means the use of mesenchymal cells derived from placenta (MSCs) and grown in PluriStem Ltd's 3-D microenvironment (including improvements to the microenvironment) for therapeutic indications including bone marrow transplant, stroke and others.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 213098

License Grant
The Israeli Licensee signed an agreement with the Israeli Licensor to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease ('GvHD').
License Property
PLX-PAD – PLacental eXpanded cells are placenta-derived cells that are designed to be administered to patients without the need for tissue or genetic matching.
Field of Use
The Licensee is a developer of placenta-based cell therapy products.

Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue from a genetically different person. GvHD is commonly associated with stem cell transplant (bone marrow transplant), but the term also applies to other forms of tissue graft. Immune cells (white blood cells) in the donated tissue (the graft) recognize the recipient (the host) as foreign (nonself).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.